2-amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists:: 1.: Structure-activity relationships and optimization of heterocyclic substituents

被引:36
作者
Slee, Deborah H. [1 ]
Chen, Yongsheng [1 ]
Zhang, Xiaohu [1 ]
Moorjani, Manisha [1 ]
Lanier, Marion C. [1 ]
Lin, Emily [1 ]
Rueter, Jaimie K. [1 ]
Williams, John P. [1 ]
Lechner, Sandra M. [2 ]
Markison, Stacy [2 ]
Malany, Siobhan [3 ]
Santos, Mark [3 ]
Gross, Raymond S. [4 ]
Jalali, Kayvon [5 ]
Sai, Yang [5 ]
Zuo, Zhiyang [5 ]
Yang, Chun [5 ]
Castro-Palomino, Julio C. [6 ]
Crespo, Maria I. [6 ]
Prat, Maria [6 ]
Gual, Silvia [6 ]
Diaz, Jose-Luis [6 ]
Saunders, John [1 ]
机构
[1] Neurocrine Biosci, Dept Med Chem, San Diego, CA 92130 USA
[2] Neurocrine Biosci, Dept Neurosci, San Diego, CA 92130 USA
[3] Neurocrine Biosci, Dept Pharmacol & Lead Discovery, San Diego, CA 92130 USA
[4] Neurocrine Biosci, Dept Chem Dev, San Diego, CA 92130 USA
[5] Neurocrine Biosci, Dept Preclin Dev, San Diego, CA 92130 USA
[6] Almirall Res Ctr, E-08980 Barcelona, Spain
关键词
D O I
10.1021/jm701185v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Previously we have described a novel series of potent and selective A(2A) receptor antagonists (e.g., 1) with excellent aqueous solubility.(1) While these compounds are efficacious A(2A) antagonists in vivo, the presence of an unsubstituted furyl moiety was a cause of some concern. In order to avoid the potential metabolic liabilities that could arise from an unsubstituted fury] moiety, an optimization effort was undertaken with the aim of replacing the unsubstituted furan with a more metabolically stable group while maintaining potency and selectivity. Herein, we describe the synthesis and SAR of a range of novel heterocyclic systems and the successful identification of a replacement for the unsubstituted furan moiety with a methylfuran or thiazole moiety while maintaining potency and selectivity.
引用
收藏
页码:1719 / 1729
页数:11
相关论文
共 35 条
[1]   Pyrazolo [4,3-e][1,2,4]triazolo[1,5-c]pyrimidine template:: Organic and medicinal chemistry approach [J].
Baraldi, PG ;
Tabrizi, MA ;
Romagnoli, R ;
El-Kashef, H ;
Preti, D ;
Bovero, A ;
Fruttarolo, F ;
Gordaliza, M ;
Borea, PA .
CURRENT ORGANIC CHEMISTRY, 2006, 10 (03) :259-275
[2]   A SYNTHESIS OF 2-(2-PYRIDINYL)IMIDAZOLES AND 4(5)-(2-PYRIDINYL)IMIDAZOLES BY PALLADIUM-CATALYZED CROSS-COUPLING REACTIONS [J].
BELL, AS ;
ROBERTS, DA ;
RUDDOCK, KS .
TETRAHEDRON LETTERS, 1988, 29 (39) :5013-5016
[3]   A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease [J].
Bibbiani, F ;
Oh, JD ;
Petzer, JP ;
Castagnoli, N ;
Chen, JF ;
Schwarzschild, MA ;
Chase, TN .
EXPERIMENTAL NEUROLOGY, 2003, 184 (01) :285-294
[4]   Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics [J].
Blum, D ;
Hourez, R ;
Galas, MC ;
Popoli, P ;
Schiffmann, SN .
LANCET NEUROLOGY, 2003, 2 (06) :366-374
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   Highlights on the development of A2A adenosine receptor agonists and antagonists [J].
Cristalli, Gloria ;
Cacciari, Barbara ;
Dal Ben, Diego ;
Lambertucci, Catia ;
Moro, Stefano ;
Spalluto, Giampiero ;
Volpini, Rosaria .
CHEMMEDCHEM, 2007, 2 (03) :260-281
[7]   Biotransformation reactions of five-membered aromatic heterocyclic rings [J].
Dalvie, DK ;
Kalgutkar, AS ;
Khojasteh-Bakht, SC ;
Obach, RS ;
O'Donnell, JP .
CHEMICAL RESEARCH IN TOXICOLOGY, 2002, 15 (03) :269-299
[8]   Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists [J].
Dowling, JE ;
Vessels, JT ;
Haque, S ;
Chang, HX ;
van Vloten, K ;
Kumaravel, G ;
Engber, T ;
Jin, XW ;
Phadke, D ;
Wang, J ;
Ayyub, M ;
Petter, RC .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) :4809-4813
[9]  
Evans DA, 2000, ANGEW CHEM INT EDIT, V39, P2536, DOI 10.1002/1521-3773(20000717)39:14<2536::AID-ANIE2536>3.0.CO
[10]  
2-U